123 related articles for article (PubMed ID: 18926796)
1. Latent membrane protein-1 of Epstein-Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines.
Rahadiani N; Takakuwa T; Tresnasari K; Morii E; Aozasa K
Biochem Biophys Res Commun; 2008 Dec; 377(2):579-583. PubMed ID: 18926796
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.
Lin KM; Lin SJ; Lin JH; Lin PY; Teng PL; Wu HE; Yeh TH; Wang YP; Chen MR; Tsai CH
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776277
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a.
Motsch N; Pfuhl T; Mrazek J; Barth S; Grässer FA
RNA Biol; 2007 Nov; 4(3):131-7. PubMed ID: 18347435
[TBL] [Abstract][Full Text] [Related]
4. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways.
Goormachtigh G; Ouk TS; Mougel A; Tranchand-Bunel D; Masy E; Le Clorennec C; Feuillard J; Bornkamm GW; Auriault C; Manet E; Fafeur V; Adriaenssens E; Coll J
J Virol; 2006 Aug; 80(15):7382-93. PubMed ID: 16840319
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
6. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.
Cahir-McFarland ED; Carter K; Rosenwald A; Giltnane JM; Henrickson SE; Staudt LM; Kieff E
J Virol; 2004 Apr; 78(8):4108-19. PubMed ID: 15047827
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway.
Gatto G; Rossi A; Rossi D; Kroening S; Bonatti S; Mallardo M
Nucleic Acids Res; 2008 Nov; 36(20):6608-19. PubMed ID: 18940871
[TBL] [Abstract][Full Text] [Related]
8. The Latent Membrane Protein 1 (LMP1).
Kieser A; Sterz KR
Curr Top Microbiol Immunol; 2015; 391():119-49. PubMed ID: 26428373
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation.
Luftig M; Yasui T; Soni V; Kang MS; Jacobson N; Cahir-McFarland E; Seed B; Kieff E
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):141-6. PubMed ID: 14691250
[TBL] [Abstract][Full Text] [Related]
10. A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways.
Adriaenssens E; Mougel A; Goormachtigh G; Loing E; Fafeur V; Auriault C; Coll J
Oncogene; 2004 Apr; 23(15):2681-93. PubMed ID: 14767477
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways.
Cameron JE; Yin Q; Fewell C; Lacey M; McBride J; Wang X; Lin Z; Schaefer BC; Flemington EK
J Virol; 2008 Feb; 82(4):1946-58. PubMed ID: 18057241
[TBL] [Abstract][Full Text] [Related]
12. The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway.
Vockerodt M; Haier B; Buttgereit P; Tesch H; Kube D
Virology; 2001 Feb; 280(2):183-98. PubMed ID: 11162833
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways.
Chen CC; Chen LC; Liang Y; Tsang NM; Chang YS
Cell Signal; 2010 Jul; 22(7):1132-42. PubMed ID: 20214978
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.
Wakisaka N; Kondo S; Yoshizaki T; Murono S; Furukawa M; Pagano JS
Mol Cell Biol; 2004 Jun; 24(12):5223-34. PubMed ID: 15169887
[TBL] [Abstract][Full Text] [Related]
15. NF-kappaB only partially mediates Epstein-Barr virus latent membrane protein 1 activation of B cells.
Liljeholm S; Hughes K; Grundström T; Brodin P
J Gen Virol; 1998 Sep; 79 ( Pt 9)():2117-25. PubMed ID: 9747720
[TBL] [Abstract][Full Text] [Related]
16. The copy number of Epstein-Barr virus latent genome correlates with the oncogenicity by the activation level of LMP1 and NF-κB.
Zuo L; Yu H; Liu L; Tang Y; Wu H; Yang J; Zhu M; Du S; Zhao L; Cao L; Li G; Lu J
Oncotarget; 2015 Dec; 6(38):41033-44. PubMed ID: 26517512
[TBL] [Abstract][Full Text] [Related]
17. EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.
Guasparri I; Bubman D; Cesarman E
Blood; 2008 Apr; 111(7):3813-20. PubMed ID: 18230756
[TBL] [Abstract][Full Text] [Related]
18. Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes.
Thornburg NJ; Raab-Traub N
J Virol; 2007 Dec; 81(23):12954-61. PubMed ID: 17881446
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b.
Anastasiadou E; Boccellato F; Vincenti S; Rosato P; Bozzoni I; Frati L; Faggioni A; Presutti C; Trivedi P
Oncogene; 2010 Mar; 29(9):1316-28. PubMed ID: 19966860
[TBL] [Abstract][Full Text] [Related]
20. Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1.
Thompson MP; Aggarwal BB; Shishodia S; Estrov Z; Kurzrock R
Leukemia; 2003 Nov; 17(11):2196-201. PubMed ID: 14523478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
